| Business Summary | | PAREXEL
International
Corporation
is
a
contract
research,
medical
marketing
and
consulting
services
organization
providing
a
broad
spectrum
of
services
from
first-in-human
clinical
studies
through
product
launch
to
the
pharmaceutical,
biotechnology
and
medical
device
industries
around
the
world.
The
Company's
service
offerings
include
clinical
trials
management,
data
management,
biostatistical
analysis,
medical
marketing,
clinical
pharmacology,
regulatory
and
medical
consulting,
industry
training
and
publishing
and
other
drug
development
consulting
services.
PAREXEL
has
internally
organized
its
operations
into
three
interactive
business
units,
Contract
Research
Services,
Medical
Marketing
Services
and
Consulting
Services. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | PRXL
is
a
contract
research
organization,
providing
product
development
and
product
launch
services
to
the
pharmaceutical,
biotechnology,
and
medical
device
industries.
For
the
nine
months
ended
3/31/01,
revenues
fell
2%
to
$280.9
million.
Net
income
fell
9%
to
$2.8
million.
Revenues
reflect
the
contract
cancellations
and
decreased
Perceptive
income.
Net
income
reflects
increased
direct
costs,
higher
staffing,
training,
retention
and
facility
related
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
106,699;
after
tax
earnings
were
-3,580. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Josef Von Rickenbach, 45 Chairman,
CEO | $387K | Carl Spalding Pres,
COO | -- | James Winschel, 51 CFO,
Sr. VP | -- | Andrew Morffew, Ph.D., 50 Pres,
PAREXEL Consulting Group | 224K | Barry Philpott, 51 Pres
of Clinical Research Services | 253K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|